People with cystic fibrosis (CF) treated with Kalydeco (ivacaftor) may have higher levels of the medication in their…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Treatment with the triple-combination therapy Trikafta improved lung function and eased respiratory symptoms for school-aged children with cystic…
Efforts to promote physical activity in people with cystic fibrosis (CF) should be holistically integrated into routine care, rather…
Targeting a protein called eRF3a may offer a way of treating cystic fibrosis (CF) caused by nonsense mutations, potentially…
More than half of adults with cystic fibrosis (CF) who underwent assessments of bone mineral density at a U.S.
Among babies with cystic fibrosis (CF) identified via newborn screening, there are marked delays in the start of care…
A Phase 1 clinical trial of an experimental inhalation gene therapy for cystic fibrosis (CF) — KB407 by…
Infusions with a hormone called GLP-1 boosted insulin production in cystic fibrosis (CF) patients with impaired glucose tolerance, according…
People with cystic fibrosis (CF) who use inhaled antibiotics are at more than three times higher risk of becoming…
Treatment with Kalydeco (ivacaftor) significantly reduces the levels of inflammatory molecules in the lungs of preschool-age children with…